Ibio (IBIO) AI Stock Analysis

• Market Cap: $45.20M
• Dividend Yield: N/A
• Average Volume (3M): 9.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 185.71%
• EPS Growth: 79.03%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 22,487,309
• 10 Day Avg. Volume: 25,804,059
• 30 Day Avg. Volume: 9,278,343
• PEG Ratio: <0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.05
• Enterprise Value/Revenue: -4.83
• Enterprise Value/Gross Profit: -11.45
• Enterprise Value/Ebitda: 0.13
• 1Y Price Target: $4.75
• Price Target Upside: 152.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.27
• Revenue Forecast (FY): $300.00K

• Rating: 55 Neutral
• Price Target: $2.50 ▲(32.98% Upside)

The overall stock score is driven by significant financial challenges, despite positive technical indicators and promising corporate developments. The financial instability and negative valuation metrics weigh heavily on the score, while recent corporate events provide some optimism.

Positive Factors

Innovative Product Development

The promising preclinical data for IBIO-610 suggests potential for a leading therapy in obesity and cardiometabolic diseases, enhancing iBio's market position and product portfolio in the long term.

Regulatory Compliance

Regaining Nasdaq compliance ensures continued access to capital markets, supporting long-term financial stability and investor confidence.

Strategic Partnerships

Strategic partnerships and licensing agreements diversify revenue streams and leverage external expertise, enhancing iBio's innovation and market reach.

Negative Factors

Financial Instability

Ongoing financial instability with persistent losses and negative cash flows threatens long-term sustainability and limits growth opportunities.

Profitability Challenges

Consistently negative net profit margins and operational inefficiencies hinder iBio's ability to achieve profitability, impacting long-term financial health.

Cash Flow Management

Negative cash flow from operations indicates insufficient cash generation to cover losses, posing risks to financial stability and operational continuity.

Ibio Business Overview & Revenue Model

Company Description

Ibio, Inc. is a biotechnology company specializing in the development and commercialization of innovative therapeutic and prophylactic products. The company focuses on plant-based protein expression technologies, offering solutions primarily in the pharmaceutical sector. Ibio's core products include biologics for various applications, including vaccines and therapeutic proteins, leveraging its proprietary FastPharming System to produce proteins in plants efficiently and at scale.

How the Company Makes Money

Ibio generates revenue through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with other biotech firms and academic institutions to co-develop its products, sharing in the financial benefits of successful outcomes. Additionally, Ibio may receive upfront payments, milestone payments, and royalties from its partners based on the sales of products developed using its technology. The revenue model is further supported by grants and contracts, particularly for vaccine development and other projects that align with public health initiatives.

Ibio Financial Statement Overview

Summary

Ibio faces significant financial challenges, with persistent losses and negative cash flows. Despite a low debt-to-equity ratio, the company's inability to generate profits and positive cash flow raises concerns about its long-term sustainability.

Income Statement

Ibio's income statement reveals significant challenges with profitability. Despite a slight revenue growth of 6.67% in the latest year, the company has consistently reported negative net profit margins, with the most recent at -45.94%. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiencies. The gross profit margin remains positive, but the overall financial health is hindered by substantial losses.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.24, suggesting manageable leverage levels. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio indicates a moderate level of equity financing, but the persistent losses pose a risk to financial stability.

Cash Flow

Cash flow analysis highlights ongoing cash flow challenges. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. Free cash flow growth is negative, and the free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported losses, but overall cash management remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	500.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	211.00K	400.00K	225.00K	0.00	-1.91M	909.00K
EBITDA	-18.78M	-17.04M	-14.02M	-27.85M	-25.72M	-28.55M
Net Income	-20.11M	-18.38M	-24.91M	-65.01M	-50.39M	-23.21M
Balance Sheet
Total Assets	64.16M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	49.57M	8.58M	14.21M	7.33M	33.52M	96.97M
Total Debt	3.29M	3.51M	4.46M	17.07M	25.77M	32.72M
Total Liabilities	8.12M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	56.04M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-17.30M	-15.32M	-18.76M	-36.17M	-45.13M	-35.23M
Operating Cash Flow	-17.25M	-15.30M	-18.55M	-30.44M	-37.80M	-30.06M
Investing Cash Flow	-21.46M	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	55.80M	8.93M	24.49M	2.30M	-5.80M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 1.88 is above the 20-day moving average (MA) of 1.69, above the 50-day MA of 1.41, and above the 200-day MA of 1.32, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 54.81 is Neutral, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	55 Neutral	$45.20M	-1.35	-54.50%	―	185.71%	79.03%
PULM	53 Neutral	$9.02M	-1.39	-79.47%	―	-99.97%	35.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FBLG	38 Underperform	$19.49M	-0.51	-1292.87%	―	―	18.47%
NERV	34 Underperform	$27.83M	-2.19	―	―	―	-323.61%
CMMB	33 Underperform	$11.94M	-1.02	-73.63%	―	―	53.19%

Ibio Corporate Events

iBio Confirms Directors and Auditor at Annual Meeting

On November 20, 2025, iBio, Inc. held its Annual Meeting of Stockholders where four proposals were voted on. The election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, was confirmed for a three-year term. Stockholders ratified Grassi & Co. as the independent auditor for the fiscal year ending June 30, 2026. Additionally, stockholders approved executive compensation on an advisory basis and decided on a one-year frequency for future advisory votes on executive compensation, aligning with the Board’s recommendation.

iBio Regains Nasdaq Compliance with Bid Price Rule

On November 4, 2025, iBio, Inc. announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. This follows a previous notification on July 29, 2025, indicating non-compliance due to the company’s stock price falling below the required threshold between June 13, 2025, and July 28, 2025. The issue is now resolved, closing the matter.

iBio Unveils Promising Preclinical Data for IBIO-610

On October 30, 2025, iBio, Inc. announced new preclinical data from its study on IBIO-610, an Activin E antibody candidate, showing an extended half-life of 33.2 days in obese non-human primates. This data, to be presented at ObesityWeek 2025, predicts a human half-life of up to 100 days, potentially allowing for twice-yearly dosing, which could significantly enhance patient experience and position IBIO-610 as a leading therapy for obesity and cardiometabolic diseases.